Familial hypertrophic cardiomyopathy

Basic concepts and future molecular diagnostics

Jessica E. Rodríguez, Christopher R. McCudden, Monte Willis

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Familial hypertrophic cardiomyopathies (FHC) are the most common genetic heart diseases in the United States, affecting nearly 1 in 500 people. Manifesting as increased cardiac wall thickness, this autosomal dominant disease goes mainly unnoticed as most affected individuals are asymptomatic. Up to 1-2% of children and adolescents and 0.5-1% adults with FHC die of sudden cardiac death, making it critical to quickly and accurately diagnose FHC to institute therapy and potentially reduce mortality. However, due to the heterogeneity of the genetic defects in mainly sarcomere proteins, this is a daunting task even with current diagnostic methods. Exciting new methods utilizing high-throughput microarray technology to identify FHC mutations by a method known as array-based resequencing has recently been described. Additionally, next generation sequencing methodologies may aid in improving FHC diagnosis. In this review, we discuss FHC pathophysiology, the rationale for testing, and discuss the limitations and advantages of current and future diagnostics.

Original languageEnglish (US)
Pages (from-to)755-765
Number of pages11
JournalClinical Biochemistry
Volume42
Issue number9
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Familial Hypertrophic Cardiomyopathy
Molecular Pathology
Microarrays
Throughput
Defects
Testing
Sarcomeres
Inborn Genetic Diseases
Proteins
Genetic Heterogeneity
Sudden Cardiac Death
Heart Diseases
Technology
Mutation
Mortality

Keywords

  • Cardiac hypertrophy
  • DNA resequencing
  • Familial hypertrophic cardiomyopathy
  • sequencing
  • Sudden cardiac death

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Familial hypertrophic cardiomyopathy : Basic concepts and future molecular diagnostics. / Rodríguez, Jessica E.; McCudden, Christopher R.; Willis, Monte.

In: Clinical Biochemistry, Vol. 42, No. 9, 01.06.2009, p. 755-765.

Research output: Contribution to journalReview article

Rodríguez, Jessica E. ; McCudden, Christopher R. ; Willis, Monte. / Familial hypertrophic cardiomyopathy : Basic concepts and future molecular diagnostics. In: Clinical Biochemistry. 2009 ; Vol. 42, No. 9. pp. 755-765.
@article{acc2ac51601d448d86698eb8c25fadbc,
title = "Familial hypertrophic cardiomyopathy: Basic concepts and future molecular diagnostics",
abstract = "Familial hypertrophic cardiomyopathies (FHC) are the most common genetic heart diseases in the United States, affecting nearly 1 in 500 people. Manifesting as increased cardiac wall thickness, this autosomal dominant disease goes mainly unnoticed as most affected individuals are asymptomatic. Up to 1-2{\%} of children and adolescents and 0.5-1{\%} adults with FHC die of sudden cardiac death, making it critical to quickly and accurately diagnose FHC to institute therapy and potentially reduce mortality. However, due to the heterogeneity of the genetic defects in mainly sarcomere proteins, this is a daunting task even with current diagnostic methods. Exciting new methods utilizing high-throughput microarray technology to identify FHC mutations by a method known as array-based resequencing has recently been described. Additionally, next generation sequencing methodologies may aid in improving FHC diagnosis. In this review, we discuss FHC pathophysiology, the rationale for testing, and discuss the limitations and advantages of current and future diagnostics.",
keywords = "Cardiac hypertrophy, DNA resequencing, Familial hypertrophic cardiomyopathy, sequencing, Sudden cardiac death",
author = "Rodr{\'i}guez, {Jessica E.} and McCudden, {Christopher R.} and Monte Willis",
year = "2009",
month = "6",
day = "1",
doi = "10.1016/j.clinbiochem.2009.01.020",
language = "English (US)",
volume = "42",
pages = "755--765",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Familial hypertrophic cardiomyopathy

T2 - Basic concepts and future molecular diagnostics

AU - Rodríguez, Jessica E.

AU - McCudden, Christopher R.

AU - Willis, Monte

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Familial hypertrophic cardiomyopathies (FHC) are the most common genetic heart diseases in the United States, affecting nearly 1 in 500 people. Manifesting as increased cardiac wall thickness, this autosomal dominant disease goes mainly unnoticed as most affected individuals are asymptomatic. Up to 1-2% of children and adolescents and 0.5-1% adults with FHC die of sudden cardiac death, making it critical to quickly and accurately diagnose FHC to institute therapy and potentially reduce mortality. However, due to the heterogeneity of the genetic defects in mainly sarcomere proteins, this is a daunting task even with current diagnostic methods. Exciting new methods utilizing high-throughput microarray technology to identify FHC mutations by a method known as array-based resequencing has recently been described. Additionally, next generation sequencing methodologies may aid in improving FHC diagnosis. In this review, we discuss FHC pathophysiology, the rationale for testing, and discuss the limitations and advantages of current and future diagnostics.

AB - Familial hypertrophic cardiomyopathies (FHC) are the most common genetic heart diseases in the United States, affecting nearly 1 in 500 people. Manifesting as increased cardiac wall thickness, this autosomal dominant disease goes mainly unnoticed as most affected individuals are asymptomatic. Up to 1-2% of children and adolescents and 0.5-1% adults with FHC die of sudden cardiac death, making it critical to quickly and accurately diagnose FHC to institute therapy and potentially reduce mortality. However, due to the heterogeneity of the genetic defects in mainly sarcomere proteins, this is a daunting task even with current diagnostic methods. Exciting new methods utilizing high-throughput microarray technology to identify FHC mutations by a method known as array-based resequencing has recently been described. Additionally, next generation sequencing methodologies may aid in improving FHC diagnosis. In this review, we discuss FHC pathophysiology, the rationale for testing, and discuss the limitations and advantages of current and future diagnostics.

KW - Cardiac hypertrophy

KW - DNA resequencing

KW - Familial hypertrophic cardiomyopathy

KW - sequencing

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=67349207405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349207405&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2009.01.020

DO - 10.1016/j.clinbiochem.2009.01.020

M3 - Review article

VL - 42

SP - 755

EP - 765

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 9

ER -